AYTU Research and Charts

AYTU - Aytu BioPharma Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-12 (Delayed quote data 2025-04-03)

Last 1.07	Change ⇓ -0.08 (-6.96%)	Volume 24,483
	Open 1.13	High 1.17	Low 1.07

8EMA (Daily) 1.17	40EMA (Daily) 1.31	50EMA (Daily) 1.35	STO (Daily) 15.000	MACD Hist (Daily) -0.010
8EMA (Weekly) 1.270	40EMA (Weekly) 1.81	50EMA (Weekly) 1.90	STO (Weekly) 5.187	MACD Hist (Weekly) -0.030


Company Profile
Aytu BioPharma Inc is a specialty pharmaceutical company commercializing novel products addressing patient needs. The company markets a portfolio of prescription products addressing large therapeutic markets. The primary care portfolio includes Natesto, the only FDA-approved nasal formulation of testosterone, ZolpiMist, the only FDA-approved oral spray prescription sleep aid, and Tuzistra XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes AcipHex Sprinkle, Cefaclor, Karbinal ER, and Poly-Vi-Flor and Tri-Vi-Flor.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.